Our businesses continued to perform well in Q3

“

All of our largest business divisions continued on a growth path in the third quarter. We have a strong focus on building Orion's future and intend to continue investing in strengthening our research and development pipeline.

Published on 28 October 2025

"In July–September 2025, our underlying (excluding major milestones) net sales increased by 24.0 percent to EUR 423.2 (341.3) million and underlying operating profit increased by 68.1 percent to EUR 121.0 (72.0) million. Our reported net sales decreased by 10.2 percent to EUR 423.2 (471.3) million and operating profit decreased by 40.1 percent to EUR 121.0 (202.0) million. The decline both in net sales and operating profit is due to major milestone payments total of EUR 130 million booked in the comparison period.

All of our largest business divisions continued on a growth path in the third quarter. The reported net sales of the Innovative Medicines business division declined from the comparison period due to the above-mentioned major milestone payments, but Nubeqa's growth was strong again. Also the Generics and Consumer Health business division continued solid growth. The growth rates of the Branded Products and the Animal Health business divisions were slightly more moderate than in the previous quarters. This is largely explained by the timing of some deliveries which is a normal variation within our business.

The tariffs set by the United States did not yet have an impact on us in Q3, and the details of the pharmaceutical industry tariffs are still not fully clear. However, we estimate that tariffs will not have a material impact on Orion this year.

In July, the European Commission approved darolutamide in combination with androgen deprivation therapy for use in patients with metastatic hormone-sensitive prostate cancer (mHSPC). This approval contributes to reinforcing Nubeqa's growth trajectory.

ODM-105 did not significantly improve the symptoms of insomnia compared to placebo in clinical Phase 2 trial, which is why we decided to discontinue the development of this molecule for the treatment of insomnia. We will focus our efforts and resources on advancing our other assets both in research and clinical phases. We are looking forward to start next year the Phase 2 programme with ODM-212 which has potential in a number of indications in oncology. This is why the Phase 2 programme will be extensive. Our goal is also to bring at least one of our biological candidates to the clinical development phase next year.

We have a strong focus on building Orion's future and intend to continue investing in strengthening our research and development pipeline. Our financial targets provide us with a good framework within which we can increase our investments.”